Literature DB >> 25985569

The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males.

Xiao-Ya Lou, Wei Zhang, Guo Wang, Dong-Li Hu, Dong Guo, Zhi-Rong Tan, Hong-Hao Zhou, Yao Chen, Hei-Hua Bao.   

Abstract

This study was designed to investigate the potential association between NTCP c.800C >T polymorphism and rosuvastatin pharmacokinetics in Chinese healthy males. 305 individuals were enrolled to identify NTCP c.800C > T, OATP1B1 c.521T > C and BCRP c.421C > A genotypes by direct sequencing and pyrosequencing methods, respectively. 17 healthy volunteers who were OATP1B1 c.521TT and BCRP c.421CC wild-type homozygotes with different NTCP c.800C > T genotype were selected to participate in this pharmacokinetic study. Nine were NTCP c.800CC wild-type homozygotes and the other eight subjects were carriers with at least one c.800T variant allele (seven subjects with c.800CT genotype and one was homozygote of c.800TT). All the subjects received a single oral dose of 10 mg rosuvastatin. The plasma concentrations of rosuvastatin were measured up to 72 h by a LC-MS method. NTCP c.800C > T genetic polymorphism markedly effected rosuvastatin pharmacokinetics. The AUC(o-72) and AUC(0 --> ∞) in subjects with NTCP c.800CT + TT genotype were 56% (162.64 ± 37.55 vs. 103.99 ± 28.15 ng x h/ml, P = 0.016) and 57% greater (178.51 ± 42.75 vs. 113.60 ± 33.73 ng x h/ml, P = 0.020) than those in the c.800CC wild-type subjects, respectively. In the c.800CT + TT mutant group, the C(max) was about 78% higher than those in c.800CC genotype (14.31 ± 3.63 vs. 8.04 ± 1.72 ng x h/ml, P = 0.004). The oral clearance (CL/F) of rosuvastatin in subjects with the c.800CT+TT genotype was only 63% of those in the c.800CC genotype (58.32 ± 12.16 vs. 93.04 ± 20.61 ng x h/ml, P = 0.009). The half-time (T1/2) and the T(max) had no significant difference between two groups (p = 0.466 and 0.713, respectively). NTCP c.800C > T polymorphism play a critical role in the individual variability of rosuvastatin pharmacokinetics in Chinese healthy males after excluding the impact of OATP1B1 c.521T > C and BCRP c.421C > A polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25985569

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  5 in total

1.  Response to perioperative statin therapy in cardiac surgery: a matter of race and timing?

Authors:  Tyler P Rasmussen; Prashant D Bhave
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

2.  Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail.

Authors:  Peter Stopfer; Thomas Giessmann; Kathrin Hohl; Ashish Sharma; Naoki Ishiguro; Mitchell E Taub; Arvid Jungnik; Dietmar Gansser; Thomas Ebner; Fabian Müller
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-02       Impact factor: 2.441

Review 3.  Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets.

Authors:  Yueran Yu; Shangda Li; Weifeng Liang
Journal:  Emerg Microbes Infect       Date:  2018-07-26       Impact factor: 7.163

4.  Diverse Effects of the NTCP p.Ser267Phe Variant on Disease Progression During Chronic HBV Infection and on HBV preS1 Variability.

Authors:  Fangji Yang; Lina Wu; Wenxiong Xu; Ying Liu; Limin Zhen; Gang Ning; Jie Song; Qian Jiao; Yongyuan Zheng; Tongtong Chen; Chan Xie; Liang Peng
Journal:  Front Cell Infect Microbiol       Date:  2019-03-01       Impact factor: 5.293

5.  Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.

Authors:  P Stopfer; T Giessmann; K Hohl; A Sharma; N Ishiguro; M E Taub; H Zimdahl-Gelling; D Gansser; M Wein; T Ebner; F Müller
Journal:  Clin Pharmacol Ther       Date:  2016-07-29       Impact factor: 6.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.